OverviewSuggest Edit

Kymab is a biopharmaceutical company which discovers and develops human monoclonal antibody therapeutics. The Company focuses on using the Kymouse platform for the discovery, development, and commercialization of monoclonal antibodies to difficult and novel drug targets in various therapeutic areas. Its pipeline products cover immuno-oncology, immunology, and opportunistic therapeutic spaces.

TypePrivate
Founded2009
HQBabraham, GB
Websitekymab.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Sept 2021)169(+2%)
Cybersecurity ratingBMore

Key People/Management at Kymab

Simon Sturge

Simon Sturge

Chief Executive Officer, Director
Anne Hyland

Anne Hyland

Chief Financial Officer & Company Secretary
Glenn A Friedrich

Glenn A Friedrich

Chief Operating Officer
Christian Itin

Christian Itin

Non-Executive Director
Tan Li

Tan Li

Non-Executive Director
Allan Bradley

Allan Bradley

Chief Scientific Officer, Director
Show more

Kymab Office Locations

Kymab has an office in Babraham
Babraham, GB (HQ)
Meditrina Building 260 Babraham Research Campus
Show all (2)

Kymab Financials and Metrics

Summary Metrics

Founding Date

2009

Kymab total Funding

$220.4 m

Kymab latest funding size

$100 m

Time since last funding

5 years ago

Kymab investors

Kymab's latest funding round in November 2016 was reported to be $100 m. In total, Kymab has raised $220.4 m
Show all financial metrics

Kymab Revenue

GBPFY, 2011FY, 2012

Current Assets

1.01.0

Total Assets

1.01.0

Common Stock

1.01.0

Total Equity

1.01.0
FY, 2011

Financial Leverage

1 x
Show all financial metrics

Kymab Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Kymab Online and Social Media Presence

Embed Graph

Kymab News and Updates

MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors

ZUG, Switzerland, Aug. 10, 2021 /PRNewswire/ -- MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the appointment of Mr. Sturge as Chairman. He has 40 years of...

ORI Capital exits Kymab in $1.1b deal with Sanofi, hits first close of $400m second fund

The firm has raised $112m so far for ORI Healthcare Fund II. The post ORI Capital exits Kymab in $1.1b deal with Sanofi, hits first close of $400m second fund appeared first on DealStreetAsia.

Sanofi to Buy Antibody Maker Kymab in $1.45 Billion Deal

Sanofi to Buy Antibody Maker Kymab in $1.45 Billion Deal

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

Kymab Frequently Asked Questions

  • When was Kymab founded?

    Kymab was founded in 2009.

  • Who are Kymab key executives?

    Kymab's key executives are Simon Sturge, Anne Hyland and Glenn A Friedrich.

  • How many employees does Kymab have?

    Kymab has 169 employees.

  • Who are Kymab competitors?

    Competitors of Kymab include Histocell, Centurion and Intra-Cellular Therapies.

  • Where is Kymab headquarters?

    Kymab headquarters is located at Meditrina Building 260 Babraham Research Campus, Babraham.

  • Where are Kymab offices?

    Kymab has an office in Babraham.

  • How many offices does Kymab have?

    Kymab has 2 offices.